Melanoma blood marker study
Part of Cancer, Skin clinical trials.
This study looks at small molecules in your blood (called the metabolome) using special tests. Researchers want to see if these molecules change depending on how your melanoma progresses, which may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had melanoma (a type of skin cancer) at some point in your life.
- You are currently being treated or followed up at the Skin Cancer Centre at Dresden University Hospital.
- You are willing to take part in the study.
- You can understand the study and give your own permission to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This research study analyzes blood and tissue samples from melanoma patients to identify biological markers that could help doctors better understand and treat the disease. Researchers will examine archived tissue samples and blood work to develop improved diagnostic tools.
This study looks at how the body's metabolism might affect the spread of melanoma. Researchers want to see if certain metabolic traits in people with melanoma are linked to a higher risk of the cancer spreading.
This study looks at serial (repeated) tumour biopsies and blood samples in people with advanced melanoma. The goal is to understand biomarkers and disease changes over time, which may help improve future treatment decisions.
This study checks whether blood “biomarkers” (measurable signs in serum) can help diagnose metastatic uveal melanoma. If you have uveal melanoma, the study may look at how useful these blood tests are for spotting spread to other parts of the body.
This trial is testing a simple blood test (liquid biopsy) to track how well melanoma responds to immunotherapy. It might help doctors decide if treatment is working or needs to be changed.
Hear when a new Melanoma of Skin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.